200432-86-6 Usage
Uses
Used in Pharmaceutical Industry:
UB 165 Fumarate is used as a therapeutic agent for the treatment of neurological disorders. Its agonistic action on presynaptic nicotinic acetylcholine receptors helps in enhancing cognitive function and memory, making it a promising candidate for the treatment of conditions such as Alzheimer's disease and other cognitive impairments.
Used in Research Applications:
UB 165 Fumarate is also used as a research tool in the field of neuroscience. Its ability to modulate nicotinic acetylcholine receptors makes it useful for studying the role of these receptors in cognitive function and the development of potential therapeutic agents for neurological disorders.
Used in Drug Development:
UB 165 Fumarate serves as a lead compound in the development of new drugs targeting nicotinic acetylcholine receptors. Its unique properties and immediate potency make it a valuable asset in the search for more effective treatments for cognitive disorders and other related conditions.
Biological Activity
Subtype-selective nicotinic agonist. Full agonist at α 3 β 2- and very weak partial agonist at α 4 β 2- containing nAChRs. K i values are 0.27, 20 (IC 50 ), 2790 and 990 nM for α 4 β 2, α 3, α 7 and α 1 β 1 δ ε respectively.
Check Digit Verification of cas no
The CAS Registry Mumber 200432-86-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,4,3 and 2 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 200432-86:
(8*2)+(7*0)+(6*0)+(5*4)+(4*3)+(3*2)+(2*8)+(1*6)=76
76 % 10 = 6
So 200432-86-6 is a valid CAS Registry Number.
200432-86-6Relevant academic research and scientific papers
Synthesis of UB-165: A novel nicotinic ligand and anatoxin- a/epibatidine hybrid
Wright, Emma,Gallagher, Timothy,Sharples, Christopher G.V.,Wonnacott, Susan
, p. 2867 - 2870 (2007/10/03)
UB-165 (5), a hybrid corresponding to natural anatoxin-a and epibatidine, has been synthesised and shows significant potency at the high affinity nicotine binding site in rat brain Ent-(5) shows a much lower level of activity which parallels the sense of enantiospecificity associated with anatoxin-a.
